Kapitalmarkt

Gesellschaftsrecht / M&A

Finanzierungen

Anlageprodukte

Steuern

ADC Therapeutics

Homburger News

Share-Image Teamplate Deals-and-Cases

Homburger advised ADC Therapeutics SA on its USD 60 m private placement of common shares and pre-funded warrants

On October 13, 2025, ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company headquartered in Switzerland, announced a USD 60 m private investment in public equity (“PIPE”) financing. In the PIPE, 11.3 m common shares and pre-funded warrants to purchase 3.8 m common shares were sold. The PIPE is led by TCGX and includes participation from Redmile Group and other existing investors.
The Homburger team was led by Daniel Häusermann (Corporate / M&amp;A, Capital Markets) and included Bianca Nedwed (Corporate / M&amp;A, Capital Markets) as well as Stefan Oesterhelt (Tax).

Corporate Governance

Finanzmarktrecht

Homburger advises OPAP on its business combination with Allwyn

On October 13, 2025, Allwyn International AG and OPAP S.A. announced that their respective boards of directors have approved the business combination of Allwyn and OPAP through an all-share transaction that values the resulting entity at an equity value of EUR 16 bn. The Combined Company will be renamed Allwyn. It will remain listed on the Main Market of the Athens Stock Exchange and intends to pursue an additional listing on another leading international exchange such as London or in New York following closing.
The transaction will bring together two leading gaming operators, creating the second largest listed gaming entertainment company globally, with multiple diverse, fast-growing and market-leading positions across Europe, the United States and other international markets.
The Homburger team includes Anna Peter, Flavio Romerio and Bianca Nedwed (all Corporate / M&amp;A).

20250619_ADC Therapeutics

Homburger advised ADC Therapeutics SA on its USD 100 m private placement of common shares and pre-funded warrants

On June 12, 2025, ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company headquartered in Switzerland, announced the private placement of 13.0 m common shares and pre-funded warrants to purchase 15.7 m common shares, raising aggregate gross proceeds of USD 100 m.
The Homburger team was led by Daniel Häusermann (Corporate / M&amp;A, Capital Markets) and included Bianca Nedwed and Estelle Piccard (both Corporate / M&amp;A, Capital Markets) as well as Stefan Oesterhelt and Philippe Weber (both Tax).

Bianca
Nedwed

Homburger advised ADC Therapeutics SA on its USD 60 m private placement of common shares and pre-funded warrants

Homburger advises OPAP on its business combination with Allwyn

Homburger advised ADC Therapeutics SA on its USD 100 m private placement of common shares and pre-funded warrants

Join the Team

Bianca Nedwed

Karriere

Sprachen

Zulassung

Teams

BiancaNedwed

Homburger advised ADC Therapeutics SA on its USD 60 m private placement of common shares and pre-funded warrants

Homburger advises OPAP on its business combination with Allwyn

Homburger advised ADC Therapeutics SA on its USD 100 m private placement of common shares and pre-funded warrants

Join the Team

Bianca Nedwed

Karriere

Sprachen

Zulassung

Teams

Bianca
Nedwed